Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 20/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21248056 | 0.91 | CFTR (0.59) | CFTR | |
| SCHEMBL25798608 | 0.90 | CFTR (0.58) | CFTR | |
| SCHEMBL16450584 | 0.86 | CFTR (0.75) | CFTR | |
| SCHEMBL16446418 | 0.83 | CFTR (0.51) | CFTR | |
| SCHEMBL16445459 | 0.83 | CFTR (1.00) | CFTR | |
| SCHEMBL16446021 | 0.82 | CFTR (0.70) | CFTR | |
| SCHEMBL16445888 | 0.82 | CFTR (0.68) | CFTR | |
| SCHEMBL16445904 | 0.82 | CFTR (0.77) | CFTR | |
| SCHEMBL16446517 | 0.82 | CFTR (0.53) | CFTR | |
| SCHEMBL16446773 | 0.82 | CFTR (0.53) | CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2021-07-20 | — | — | US | claimed |
| US-20250114343-A1 | Treatment of Bronchiectasis | UNIV EMORY (US) | 2025-04-10 | — | — | US | disclosed |
| EP-4465987-A1 | TREATMENT OF BRONCHIECTASIS | Emory University (US) | 2024-11-27 | — | — | EP | disclosed |
| WO-2024196879-A1 | PHOSPHODIESTERASE 4 INHIBITORS FOR MANAGING RESPIRATORY DISEASES OR CONDITIONS | EMORY UNIVERSITY (US) | 2024-09-26 | — | — | WO | disclosed |
| US-20230355607-A1 | NEW MEDICAL USE OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) MODULATORS | CHARITE-UNIVERSITATSMEDIZIN BERLIN (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230355607-A1 | NEW MEDICAL USE OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) MODULATORS | CHARITE-UNIVERSITATSMEDIZIN BERLIN (DE) | 2023-11-09 | — | — | US | disclosed |
| EP-4268824-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZINE DERIVATIVES USEFUL AS A MEDICAMENT | Manros Therapeutics (FR) | 2023-11-01 | — | — | EP | disclosed |
| EP-4245302-A1 | CFTR MODULATORS FOR THE TREATMENT OF VASCULAR DISEASE | Charité - Universitätsmedizin Berlin (DE) | 2023-09-20 | — | — | EP | disclosed |
| WO-2023141458-A1 | TREATMENT OF BRONCHIECTASIS | EMORY UNIVERSITY (US) | 2023-07-27 | — | — | WO | disclosed |
| EP-4213837-A1 | NEW MEDICAL USE OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) MODULATORS | Charité - Universitätsmedizin Berlin (DE) | 2023-07-26 | — | — | EP | disclosed |
| US-20160317493-A1 | Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Cystic Fibrosis | GILEAD SCIENCES, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9351955-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2016-05-31 | — | — | US | disclosed |
| US-9351955-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2016-05-31 | — | — | US | disclosed |
| US-20160022633-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160022633-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2016-01-28 | — | — | US | disclosed |
| US-9133210-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2015-09-15 | — | — | US | disclosed |
| US-9133210-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2015-09-15 | — | — | US | disclosed |
| WO-2015018823-A1 | THIENO[2,3-C]PYRANS AS CFTR MODULATORS | GALAPAGOS NV (BE) | 2015-02-12 | — | — | WO | disclosed |
| US-20150045327-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20150045327-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | CFTR 1/4885 |
| US-20160022633-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | CFTR 1/4885 |
| US-20160317493-A1 | Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Cystic Fibrosis | CFTR, ABCB11, ABCC5 | CFTR 1/4885 |
| US-20230355607-A1 | NEW MEDICAL USE OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) MODULATORS | CFTR, SCNN1B, SLC26A4 | CFTR 1/4885 |
| US-20150045327-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | CFTR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.